STAT+: Mirati’s KRAS-blocking lung cancer drug clears safety hurdle in combination study

Mirati Therapeutics said Monday that its KRAS-targeting cancer drug called adagrasib combined with another immunotherapy was well-tolerated by patients with lung cancer.